[go: up one dir, main page]

NO20016034L - Inhibitorer av aspartylprotease - Google Patents

Inhibitorer av aspartylprotease

Info

Publication number
NO20016034L
NO20016034L NO20016034A NO20016034A NO20016034L NO 20016034 L NO20016034 L NO 20016034L NO 20016034 A NO20016034 A NO 20016034A NO 20016034 A NO20016034 A NO 20016034A NO 20016034 L NO20016034 L NO 20016034L
Authority
NO
Norway
Prior art keywords
inhibitors
aspartyl protease
aspartyl
protease
Prior art date
Application number
NO20016034A
Other languages
English (en)
Other versions
NO323951B1 (no
NO20016034D0 (no
Inventor
Michael Robin Hale
Roger D Tung
Stephen Price
Robin David Wilkes
Wayne Carl Schairer
Ashley Nicholas Jarvis
Andrew Spaltenstein
Eric Steven Furfine
Vicente Samano
Istvan Kaldor
John Franklin Miller
Michael Stephen Brieger
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20016034D0 publication Critical patent/NO20016034D0/no
Publication of NO20016034L publication Critical patent/NO20016034L/no
Publication of NO323951B1 publication Critical patent/NO323951B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20016034A 1999-06-11 2001-12-10 Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse NO323951B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13907099P 1999-06-11 1999-06-11
US19021100P 2000-03-17 2000-03-17
PCT/US2000/015781 WO2000076961A1 (en) 1999-06-11 2000-06-08 Inhibitors of aspartyl protease

Publications (3)

Publication Number Publication Date
NO20016034D0 NO20016034D0 (no) 2001-12-10
NO20016034L true NO20016034L (no) 2002-01-18
NO323951B1 NO323951B1 (no) 2007-07-23

Family

ID=26836833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016034A NO323951B1 (no) 1999-06-11 2001-12-10 Sulfonamider som er inhibitorer av aspartylprotease, sammensetninger inneholdende disse og deres anvendelse

Country Status (31)

Country Link
EP (2) EP1686113B1 (no)
JP (2) JP4503896B2 (no)
KR (1) KR100762188B1 (no)
CN (2) CN100516034C (no)
AR (1) AR031520A1 (no)
AT (2) ATE534622T1 (no)
AU (1) AU779994B2 (no)
BR (1) BR0011745A (no)
CA (1) CA2380858C (no)
CO (1) CO5160337A1 (no)
CY (1) CY1112632T1 (no)
CZ (1) CZ303052B6 (no)
DE (1) DE60027722T2 (no)
DK (2) DK1194404T3 (no)
ES (2) ES2263478T3 (no)
HK (1) HK1046899B (no)
HU (1) HUP0300385A3 (no)
IL (3) IL146918A0 (no)
MX (1) MXPA01012808A (no)
MY (1) MY137777A (no)
NO (1) NO323951B1 (no)
NZ (1) NZ516003A (no)
PE (1) PE20010230A1 (no)
PL (1) PL210227B1 (no)
PT (2) PT1194404E (no)
SI (1) SI1194404T1 (no)
TN (1) TNSN00129A1 (no)
TR (3) TR200202528T2 (no)
TW (3) TWI318116B (no)
WO (1) WO2000076961A1 (no)
ZA (1) ZA200110177B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235492T3 (es) * 1998-06-19 2005-07-01 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil proteasa de tipo sulfonamida.
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
MXPA03007236A (es) 2001-02-14 2003-12-04 Tibotec Pharm Ltd 2-(amino sustituido)-benzotiazol sulfonamidas inhibidoras de proteasa de vih de amplio espectro.
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
MY142238A (en) * 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
DK1509537T3 (da) * 2002-04-26 2007-11-12 Gilead Sciences Inc Cellulær akkumulering af phosphonatanaloger af HIV-protease-inhibitorforbindelser og forbindelserne som sådanne
US6632816B1 (en) * 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
WO2005000249A2 (en) * 2003-06-27 2005-01-06 Smithkline Beecham Corporation Preparation of chemical compounds
US7767683B2 (en) 2003-08-18 2010-08-03 H. Lundbeck A/S Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
MY149978A (en) * 2003-12-15 2013-11-15 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
US7807845B2 (en) 2004-03-11 2010-10-05 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
TWI383975B (zh) 2004-03-31 2013-02-01 悌柏泰克醫藥有限公司 製備(3R,3aS,6aR)六氫-呋喃并〔2,3-b〕呋喃-3-醇之方法
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
US20080194554A1 (en) * 2005-03-11 2008-08-14 Mclean Ed W Hiv Protease Inhibitors
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
WO2008013834A1 (en) * 2006-07-24 2008-01-31 Gilead Sciences, Inc., Bisfuranyl protease inhibitors
RS51675B (sr) 2006-11-09 2011-10-31 Tibotec Pharmaceuticals Metode za dobivanje heksahidrofuro[2,3-b]furan-3-ola
WO2008133734A2 (en) * 2006-11-21 2008-11-06 Purdue Research Foundation Method and compositions for treating hiv infections
PT2152667E (pt) 2007-04-27 2011-04-06 Tibotec Pharm Ltd Processos para a preparação de derivados de n-isobutil-n- (2-hidroxi-3-amino-4-fenilbutil)-p-nitrobenzenosulfonilamida
GB2452952A (en) * 2007-09-20 2009-03-25 Npil Pharmaceuticals N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
PL2480220T3 (pl) 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
EP3192794A4 (en) * 2014-09-11 2018-06-27 Shionogi & Co., Ltd. Sustained hiv protease inhibitor
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
ES2243959T3 (es) * 1990-11-19 2005-12-01 Monsanto Company Inhibidores de proteasas retrovirales.
ES2177868T3 (es) * 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
WO1994010136A1 (en) * 1992-10-30 1994-05-11 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
EP0715618B1 (en) * 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ATE382041T1 (de) * 1995-01-20 2008-01-15 Searle Llc Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
CN1530372A (zh) * 1995-03-10 2004-09-22 G.D.ɪ����˾ 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
GB9712504D0 (en) * 1997-06-17 1997-08-20 Dundee Teaching Hospitals Nhs Thermal imaging method and apparatus
US6316405B1 (en) * 1997-08-26 2001-11-13 Wisconsin Alumni Research Foundation Cyclosporin a conjugates and uses therefor
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion

Also Published As

Publication number Publication date
SI1194404T1 (sl) 2006-10-31
CA2380858A1 (en) 2000-12-21
AU5600600A (en) 2001-01-02
PL210227B1 (pl) 2011-12-30
ZA200110177B (en) 2003-01-13
TWI318116B (en) 2009-12-11
DE60027722D1 (en) 2006-06-08
CN1361765A (zh) 2002-07-31
ATE325091T1 (de) 2006-06-15
IL202633A (en) 2013-02-28
JP2009046493A (ja) 2009-03-05
MXPA01012808A (es) 2002-07-22
CA2380858C (en) 2011-12-06
TR200202528T2 (tr) 2003-02-21
TW200425891A (en) 2004-12-01
CZ20014431A3 (cs) 2002-06-12
CO5160337A1 (es) 2002-05-30
CN100516034C (zh) 2009-07-22
ES2263478T3 (es) 2006-12-16
IL146918A0 (en) 2002-08-14
DK1686113T3 (da) 2012-02-20
NO323951B1 (no) 2007-07-23
MY137777A (en) 2009-03-31
TWI299000B (en) 2008-07-21
PE20010230A1 (es) 2001-03-15
TW593248B (en) 2004-06-21
EP1194404A1 (en) 2002-04-10
DK1194404T3 (da) 2006-09-04
EP1194404B1 (en) 2006-05-03
HK1046899A1 (en) 2003-01-30
PT1686113E (pt) 2012-02-20
KR100762188B1 (ko) 2007-10-04
CY1112632T1 (el) 2016-02-10
WO2000076961A1 (en) 2000-12-21
TR200603871T2 (tr) 2007-01-22
ATE534622T1 (de) 2011-12-15
PT1194404E (pt) 2006-08-31
HUP0300385A2 (hu) 2003-07-28
JP2003502309A (ja) 2003-01-21
HK1046899B (en) 2007-03-02
IL202633A0 (en) 2010-06-30
IL146918A (en) 2010-06-16
PL352830A1 (en) 2003-09-08
CZ303052B6 (cs) 2012-03-14
BR0011745A (pt) 2002-03-19
KR20020033642A (ko) 2002-05-07
NZ516003A (en) 2004-02-27
EP1686113A1 (en) 2006-08-02
HUP0300385A3 (en) 2007-05-29
TR200200407T2 (tr) 2002-08-21
NO20016034D0 (no) 2001-12-10
DE60027722T2 (de) 2007-04-26
TNSN00129A1 (fr) 2005-11-10
TW200804252A (en) 2008-01-16
ES2375823T3 (es) 2012-03-06
CN101245058A (zh) 2008-08-20
EP1686113B1 (en) 2011-11-23
AU779994B2 (en) 2005-02-24
AR031520A1 (es) 2003-09-24
JP4503896B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
NO20016034D0 (no) Inhibitorer av aspartylprotease
NO20003332D0 (no) Midisinforløper av aspartylproteaseinhibitorer
NO20012980D0 (no) Proteaseinhibitorer
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
ATE237329T1 (de) Metalloprotease inhibitoren
EE04466B1 (et) Sulfoonamiidi derivaadid kui aspartüülproteaasi inhibiitorid
NO20012984D0 (no) Succinoylamino benzodiazepiner som inhibitorer av AB proteinproduksjon
DE69823178D1 (de) Serine protease inhibitoren
NO983688D0 (no) Serin-protease-inhibitorer
ATE277074T1 (de) Serine-protease-inhibitoren
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
ATE221080T1 (de) Serine-protease-inhibitoren
NO20025786L (no) Protaseinhibitorer
DE60024101D1 (de) Enzyminhibitoren
NO20025005L (no) Proteaseinhibitorer
NO20013669L (no) Reverse hydroksamatinhibitorer av matriks metalloproteinaser
AU2002348465A1 (en) Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease
NO20032328D0 (no) Proteaseinhibitorer
DE60124397D1 (de) Inhibitoren von serinproteasen
EP1195163A4 (en) Serine protease inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees